

2020 TAG ANNUAL REPORT

PROGRESS IN THE FIGHT

**For Better Treatment, Prevention,
a Vaccine, and a Cure for HIV,
Tuberculosis, and Hepatitis C Virus**

TAG

Treatment Action Group

June 2021

Dear Friend of TAG:

This month marks the 40th anniversary of the U.S. government's first reports of the emergence of what later became known as AIDS. Over those four decades, 76 million people became infected with HIV, and over 33 million have died from it. Thanks to research and activism, more than 26 million of the world's 38 million people living with HIV are receiving lifesaving treatment. Though unacceptable gaps remain, the progress since — spurred in no small part by TAG's informed, targeted, and tireless activism — has been remarkable.

Over 40 individual antiretroviral treatments (ART) have been approved. From no treatment at all, ART has evolved from complicated regimens with spotty efficacy and brutal side effects to simple pills or even monthly injections that durably reduce HIV to undetectable levels. Highly effective prevention options are available. Two individuals are known to have been cured. Thanks to TAG and our partners pushing for high standards, community engagement, and health justice, I watched the transformation of HIV infection from a frequently fatal condition among my friends to what is now a preventable and treatable condition — as long as prevention, therapy, care, and information are accessible.

As the HIV epidemic changes over time, and new pandemics continue to emerge, I've been amazed and proud at how TAG continues to evolve while remaining true to its activist roots. We partner with the most affected communities in the U.S. and around the world. After TAG accelerated the development of effective ART in the mid-1990s, we moved on to catalyze advocacy movements for the two deadliest coinfections of people with HIV — tuberculosis and hepatitis C. And in 2020, we began applying our unique science-based and community-driven voice, as well as the lessons learned over the past nearly three decades, to COVID-19.

It's been such an honor to lead TAG's Board of Directors over the past 25 years. I'm pleased to announce some changes to TAG's Board of Directors. I am passing the Board President's baton to Rob Lennon, who brings his brilliant leadership and dedication to TAG's mission. The highly capable Mrinal Vikram is now our Secretary. Laura Morrison remains TAG's steadfast Treasurer. I remain forever a part of TAG's community, committed to advancing TAG's vital work to end pandemics and the inequitable structures that allow them to flourish.

Your support has been central to TAG's success over the past three decades, and particularly during this past year of overwhelming uncertainty. I know you'll find inspiration in reading about the amazing work the TAG staff and partners accomplished in spite of all the challenges during 2020. I hope you will continue — as I will — to support TAG so we can accelerate the end of these pandemics once and for all.

Yours in the fight,



Barbara Hughes

President Emeritus, Board of Directors

“Your support has been central to TAG's success over the past three decades, and particularly during this past year of overwhelming uncertainty.”

2020 RESEARCH IN ACTION AWARDS

We held our annual Research in Action Awards virtually for the first time on Thursday, November 19, 2020. Journalist and activist **Ann Northrop** was our host, and the multit talented **Rachel York** treated our audience to amazing performances. **Dr. Jonathan LaPook** of CBS News moderated a compelling roundtable discussion with panelists **Dr. Wafaa El-Sadr**, **Dr. Trip Gulick**, and **Annette Gaudino**. Our wonderful honorees were **Dr. Anthony S. Fauci**, **National Nurses United**, **Wakefield**, and **Sharon Stone**. **Mark Harrington** talked about TAG's many achievements in this difficult year, and our event chair **Bob Bronzo** made a moving appeal. Cameos, many of them from previous RIAA honorees, lit up the screen: Amanda Lugg, Peter Staley, Lynda Dee, Greg Millett, Dr. Mary T. Basset, David France, Alan Cumming, Judith Light, Matthew Lopez, Jon Cohen, Kevin Goetz, and Barbara Hughes. You can relive the wonderful evening [here](#).

Anthony S. Fauci, M.D.



“ And so, to my dear friends and colleagues with whom I have worked with at TAG, thank you very much for this award. It means a great deal to me. Together, we have accomplished much, and for this, we can feel proud and energized for the inevitable challenges ahead.”

Bonnie Castillo, National Nurses United



“ All along the way we have spoken up for our Black, Brown, and Indigenous patients who have been hit hard by this pandemic, especially given the racial injustice that is inseparable from health care injustice in this country.”

Sharon Stone



“ I'm here to scream for joy for all the work that you're doing at TAG, and I'm here to say, I could not be more humbled, more honored, or more devoted to this journey in my life to end HIV/AIDS in my lifetime and to continue to work with the Treatment Action Group in whatever way they'll have me.”

Wakefield



“ This award from TAG touches me most deeply, however, because our association did not begin with the current pandemic; we go back decades. We have gone through the wars together.”

HIV PROJECT

- TAG's Basic Science, Vaccines, and Cure Project Director Richard Jefferys published an analysis of HIV cure-related clinical trials, highlighting important issues such as the continuing underrepresentation of women. Richard spoke to the *New York Times* about the second individual to be cured of HIV.
- TAG hired **Edric Figueroa** as the first ACT NOW: END AIDS (ANEA) Coalition Coordinator. With ANEA, we supported diverse community groups in Alabama, Dallas, Los Angeles, Memphis, and New Orleans to fund and carry out local work to end the HIV epidemics there.
- HIV Project Director Jeremiah Johnson and Richard **published results** of a survey on community perspectives on the future of HIV prevention trials for the HIV Vaccine Trials Network (HVTN).
- TAG published four TAG **HIV pipeline reports**, along with its first **COVID-19 pipeline**.
- TAG waged a successful campaign with partners to ensure the participation of people with HIV in the phase III COVID-19 vaccine trials sponsored by **Moderna** and Pfizer.
- With allies, TAG launched a call to end racism and over-policing in NYC, called on New York's **Board of Health** to declare these a **public health emergency**, and deplored the politically motivated **resignation** of NYC Health Commissioner Dr. Oxiris Barbot.
- TAG's "Landscape Analysis of HIV Cure-Related Clinical Research" was **published in the Journal of Virus Eradication**, and a companion community summary was made available on our website.
- ANEA launched a new website and revised the executive summary for the coalition's **community roadmap** to end HIV in the U.S.
- TAG hired our first HIV Community Engagement Officer, **Abraham Johnson, MPH**, to strengthen **community involvement** with the HIV Vaccine Trials Network, Black AIDS Institute, and the COVID Prevention and Vaccine Trials Network (CoVPN).
- Edric, speaking for ANEA, participated in a panel at the Presidential Advisory Council on HIV/AIDS (PACHA) meeting on the **future of the federal ending HIV Initiative**. ANEA provided a **robust transition memo** to the Biden-Harris Administration detailing the need for a human rights approach and community leadership in the incoming administration's HIV response.
- TAG, in partnership with the Black AIDS Institute and the HIV Vaccine Trials Network, launched the first We The People Research Cohort to train advocates from underrepresented U.S. communities to participate in HIV prevention research advocacy.

“As a long-time activist, I cannot underestimate the importance of TAG's work in our world.

– Amanda Lugg, RIAA 2020

“Thank you, TAG, for leading the fight to end HIV, tuberculosis, and hepatitis C, and now COVID-19, for everyone around the world.

– Rachel York, RIAA 2020

TB PROJECT

- Advocacy by TAG's TB team, including members of Guideline Development Groups, resulted in strong recommendations for improved diagnostics and treatment regimens by the WHO. To help activists unpack these updated guidelines and hold governments accountable for ensuring access to higher diagnostic and treatment standards, the TB team launched *An Activist's Guide to Tuberculosis Diagnostic Tools* and *An Activist's Guide to Treatment for Drug-Resistant Tuberculosis*.
- TAG secured a **major win** for human rights when a United Nations body issued a progressive General Comment on the right to science incorporating TAG's **input**.
- TAG and civil society partners in 10 countries advocated for access to the best TB preventive therapy. TAG and partners in India, Thailand, and France successfully resisted spurious attempts by Big Pharma to patent two decades-old medicines used to prevent TB (isoniazid and rifapentine) by publishing an *Access Roadmap and Patent Landscape* on the two drugs with **statements** supporting patent oppositions.
- TAG, with the Médecins Sans Frontières (MSF) Access Campaign, expanded the scope and reach of the **Time for \$5 Campaign**, a global civil society movement calling on Cepheid to reduce the prices of Xpert rapid tests for TB, HIV, HCV, COVID-19, and other conditions to \$5.
- TAG refreshed and diversified the membership of its Global Tuberculosis Community Advisory Board (TB CAB), adding members from India, Kenya, Moldova, Peru, Ukraine, and Zimbabwe, and convened annual meetings with key TB research and product sponsors virtually.
- TAG published, in PLOS ONE, a comprehensive **review** of public, foundation, and corporate investment in developing bedaquiline, the first new TB drug in a new class approved in fifty years, showing that the public sector (mainly the U.S. government) invested between 160 percent and 500 percent more than the company in this breakthrough drug, now the cornerstone of drug-resistant TB treatment. This landmark article is among the most in-depth, comprehensive peer-reviewed articles showing the evidence for public versus private investments in developing any drug. Leveraging these findings, **TAG** and the **TB CAB** called for J&J, the manufacturer, to reduce the drug's price to \$1/ day.
- TAG's TB and policy teams launched a **policy brief** showing how tools, concepts, capacity, and infrastructure established through years of public investments in TB R&D have informed COVID-19 research and responses.
- New studies for which TAG advocated over the past decade showed that drug-sensitive TB can now be cured in four rather than six months in both adults and children. A TAG-led community advisory board played a leading role in disseminating these results.
- The TB team published four pipeline report chapters, reviewing recent progress in the development of new TB diagnostics, treatments, preventive therapy, and vaccines. With the Stop TB Partnership, TAG published *Tuberculosis Research Funding Trends, 2005–2019*, the 15th in a series of influential reports tracking global funding for TB research.
- The policy and TB teams coordinated advocacy for TB research and program investment by the U.S. Congress, promoting **increased R+D investment** and preserving TB program funding in Indiana and New York.



Whenever there's a new epidemic, like Ebola, and now COVID, AIDS activists step up to the plate. We're the first to do it, TAG is the first to do it.

– Peter Staley, RIAA 2020

POLICY 2020

- TAG's policy team achieved funding increases to many of the organization's priority issues in fiscal year (FY) 2021 appropriations, in the midst of the COVID-19 pandemic, nationwide demonstrations calling for long-overdue racial justice, and a hotly disputed election cycle. Among agencies receiving increased federal funding for fiscal year 2021 were USAID's Global Accelerator to End TB (+\$9 million), NIH HIV research (+\$14 million), CDC viral hepatitis research (+\$500,000), and the CDC's Ending the HIV Epidemic Initiative (+\$35 million).
- TAG's Senior Government Relations and Policy Officer Lizzy Lovinger spoke at the Presidential Advisory Council on HIV/AIDS (PACHA), expressing TAG's strong support for increased HIV research funding due to COVID-19 disruptions, the need for rigorous ethical standards, and the dangers of political interference in research.
- With AVAC and HealthGAP, TAG condemned the unwise U.S. move to **withdraw** its membership and funding support for the WHO.
- Lizzy was elected co-chair of the Tuberculosis Roundtable coalition, where she will lead and facilitate federal and global TB advocacy initiatives. Lizzy participated in several meetings with the Biden-Harris transition team to discuss global health community requests.
- TAG's policy team collaborated with TAG's HIV, HCV, and TB projects to publish a landmark series of policy briefs on how investments in **HIV, TB, and HCV** research have profoundly benefited and accelerated science's ability to respond to COVID-19.
- Due to the relentless advocacy of TAG's Annette Gaudino over many years, in September 2020, New York State removed prior authorization requirements for HCV cures for NYS Medicaid, correctional, and privately insured individuals, allowing combination therapy cures for hepatitis C virus (HCV) and making it easier for these New Yorkers to be cured of HCV infection. Building on this win, five additional states are now removing these barriers to HCV cures.

HCV PROJECT

- TAG convinced the President's Emergency Plan for AIDS Relief (PEPFAR) to expand its country guidance for viral hepatitis including HCV testing, treatment, and cure for people coinfecting with HIV and HCV in PEPFAR focus countries.
- TAG HCV Project Director Bryn Gay collaborated on the first meeting between harm reductionists, community representatives, and new officials at the Georgian Ministry of Health, resulting in the establishment of a ministry-community steering committee to implement treatment guideline changes, community recommendations, and action plans to reduce or eliminate HCV infection in the Republic of Georgia. Plans for sustaining engagement have been paused due to COVID-19.
- Bryn and TAG Policy Strategy Director Annette Gaudino published an **issue brief, in English and French, on difficult-to-treat hepatitis C** subtypes found in sub-Saharan Africa and its diaspora.
- The HCV and TB teams joined the Unitaid-funded LONGEVITY project to support community engagement in clinical trials development of long-acting treatments for HCV, TB, and malaria. TAG held preliminary discussions with the Medicines Patent Pool and the LONGEVITY project's commercial partner Tandem Nano Ltd to assess alternative incentives (other than exclusivity in rich countries) in the related voluntary licensing agreements, which would expand future generics access.
- Bryn catalyzed diagnostics advocacy and informed a community wishlist in Malaysia, leading to the **adoption of numerous policy changes**, such as free HCV testing and treatment, including in some harm reduction sites.
- Bryn spoke on HCV diagnostics literacy and community engagement work at a World Hepatitis Day **webinar** and made recommendations on new indicators at the first World Health Organization (WHO) Viral Hepatitis Elimination Validation meeting.

- Bryn and Annette launched the 2020 **HCV Pipeline Report**, which won praise from the Director of the CDC Division of Viral Hepatitis.
- Bryn, Mark Harrington, and Suraj Madoori met with the new WHO Head of HIV, Viral Hepatitis, and STI Division, Dr. Meg Doherty, about TAG's HCV priorities, where they gained commitments to wider community consultations and succeeded in getting our recommended community representatives accepted for the WHO Key Populations Guidelines meeting.
- Bryn provided a comprehensive and detailed orientation with our new HCV Community Engagement Officer Joelle Dountio Ofimboudem to support the LONGEVITY project's community engagement activities, particularly around long-acting formulations for HCV.
- With the TB Team, Bryn and Joelle managed consultants' preparations of a patent landscape and access strategy report for long-acting glecaprevir/pibrentasvir (Mavyret for HCV), rifapentine, isoniazid, delamanid, and bedaquiline for TB. The report will be launched in 2021 and will inform community workshops.
- Columbia University professor Wafaa El-Sadr and Mark coordinated a **letter** by the COVID Working Group urging the city to establish safe spaces for vulnerable individuals with presumed or diagnosed mild/moderate COVID-19 disease who are unable to self-isolate at home due to crowded quarters or inability to self-care. This effort influenced NYC Council legislation mandating housing for homeless persons with COVID-19.
- TAG produced a statement defending the World Health Organization from funding cuts proposed by the U.S. president.
- Annette Gaudino co-led efforts to secure the release of incarcerated persons from New York State jails and prisons to protect them from ongoing unacceptable exposure to SARS-CoV-2 and later worked to secure access to COVID-19 vaccines for this population.
- Bryn presented a **poster** on the right to science and access to COVID-19 technologies at the International AIDS Society COVID-19 Conference.
- Lizzy Lovinger delivered **TAG's testimony** at the October 22 meeting of the FDA's Vaccine and Related Biologic Products Advisory Committee meeting to support FDA's maintenance of high standards for oversight and regulatory review of potential vaccines for COVID-19 in the face of political interference.
- Annette served as the public health lead in coalition with legal advocates, contributing her expertise from the initial drafting through 11th hour amendment negotiations, persuading the NYS legislature to pass and Governor Cuomo to sign into law the first and only contact tracing confidentiality law, barring law enforcement and immigration authorities from accessing identifying information collected in the course of the COVID-19 response.

COVID-19 RESPONSE

- In March 2020, TAG rapidly and smoothly shifted its internal operations and advocacy work in response to the global COVID-19 pandemic while continuing to advance existing work in HIV, HCV, and TB research and advocacy. Jeremiah Johnson and Mark Harrington cofounded a virtual New York-focused **COVID-19 Working Group**, which several TAG staff participated in, in partnership with community partners and with support from Columbia University School of Social Work and generous gifts to TAG from long-time supporters.
- Bryn Gay drafted **global principles** on access to COVID-19 medicines, technologies, and innovation, adapted them for the U.S. context and in a letter to the G20 health ministers, and promoted them while mentoring a "squad" of activists in the Salk Advocacy Innovation Lab, a network of over 300 activists in 29 countries demanding a free and accessible vaccine for all.

Balance Sheet

	2020	2019
Assets		
Cash and cash equivalents	\$1,571,364	\$1,610,906
Unconditional Promises to Give	2,465,371	496,981
Accounts receivable	1,252	7,583
Prepaid expenses and other current assets	50,247	37,208
Donated artwork	470,239	492,739
Security deposit	72,463	72,463
Property and equipment - net	18,477	18,580
Total Assets	\$4,649,413	\$2,736,460
Liabilities and Net Assets		
Liabilities		
Accounts payable and accrued expenses	\$48,767	\$38,603
Loan Payable	214,717	
Deferred rent	18,613	33,362
Total Liabilities	282,097	71,965
Net Assets		
Without donor restrictions	1,402,831	1,537,543
With donor restrictions	2,964,485	1,126,952
Total Net Assets	4,367,316	2,664,495
Total Liabilities and Net Assets	\$4,649,413	\$2,736,460


Statement of Cash Flows

	2020	2019
Cash Flows from Operating Activities		
Increase (decrease) in net assets	\$1,702,821	(\$590,354)
Adjustments to reconcile increase (decrease) in net assets to net cash used by operating activities:		
Depreciation	9,776	9,547
(Increase) decrease in:		
Unconditional promises to give	(1,968,390)	719,890
Accounts receivable	6,331	(6,444)
Prepaid expenses and other assets	(13,039)	(5,614)
Donated artwork	22,500	(53,000)
Increase (decrease) in:		
Accounts payable and accrued expenses	10,164	13,207
Deferred rent	(14,749)	(9,158)
Net Cash Used by Operating Activities	(244,586)	78,074
Cash Flows from Investing Activities		
Acquisition of property and equipment	(9,673)	(1,399)
Net Cash Used by Investing Activities	(9,673)	(1,399)
Cash Flows from Financing Activities		
Proceeds from loan payable	214,717	-
Net decrease in cash and cash equivalents	(39,542)	76,675
Cash and cash equivalents, beginning of year	1,610,906	1,534,231
Cash and Cash Equivalents, End of Year	\$1,571,364	\$1,610,906

Statement of Activities

	2020		
	Without Donor Restrictions	With Donor Restrictions	Total
Revenue and Other Support			
Contributions	\$511,667	\$3,979,681	\$4,491,348
Fundraising benefit events	170,555	-	170,555
Less: Direct benefit expenses			
Donated artwork, goods and services	336	-	336
Art sales, net of cost of goods sold	1,700	-	1,700
Other income	25,978	-	25,978
Interest income	737	-	737
Net assets released from restrictions	2,142,148	(2,142,148)	-
Total Revenue and Other Support	<u>2,853,121</u>	<u>1,837,533</u>	<u>4,690,654</u>
Expenses			
Program Services			
HIV Program	964,172	-	964,172
Hepatitis C Virus Program	234,426	-	234,426
Tuberculosis Program	1,277,362	-	1,277,362
Total Program Services	<u>2,475,960</u>	-	<u>2,475,960</u>
Supporting Services			
Management and general	360,015	-	360,015
Fundraising	151,858	-	151,858
Total Expenses	<u>2,987,833</u>	-	<u>2,987,833</u>
Increase (decrease) in net assets	(134,712)	1,837,533	1,702,821
Net assets, beginning of year	1,537,543	1,126,952	2,664,495
Net Assets, End of Year	<u>\$1,402,831</u>	<u>\$2,964,485</u>	<u>\$4,367,316</u>

Summary of 2020 Functional Expenses



\$100,000 or more

The Aurum Institute
 Bill and Melinda Gates Foundation
 Hopewell Fund
 Fred Hutchinson Cancer Research Center
 Stop TB Partnership hosted by UNOPS
 University of Nebraska Medical Center
 ViiV Healthcare

\$50,000 to \$99,999

Broadway Cares / Equity Fights AIDS
 Merck & Co.
 Veterans Affairs Medical Center of
 Washington, DC

\$25,000 to \$49,999

The Debs Foundation: Richard A. and
 Barbara Knowles Debs; Nick Debs
 David Gold
 Housing Works
 M·A·C VIVA GLAM Fund
 Open Society Foundations

\$10,000 to \$24,999

The Calamus Foundation
 Joseph Evall and Richard M. Lynn
 Annie Bennett Glenn Fund of The
 Winston Salem Foundation
 Robert W. Lennon and Mark Gilrain
 Médecins du Monde
 National TB Controllers Association

\$5,000 to \$9,999

amfAR, The Foundation for AIDS Research
 Sam Avrett and David Barr
 Michael Becker and Tee Scaturchio
 Celeste B. Cooper
 Federation of Protestant Welfare
 Agencies
 David France
 Kevin and Neil Goetz
 Hauser & Wirth
 Marta Heflin Foundation
 Ambassador James C. Hormel and
 Michael P.N. Hormel
 Erica Lessem
 Robert Monteleone
 Laura A. Morrison
 Roche
 Jordan Roth and Richie Jackson

William Shea and Frank R. Selvaggi
 Barry C. Skovgaard and Marc Wolinsky
 John Voelcker
 Weil, Gotshal & Manges LLP

\$2,500 to \$4,999

Columbia University
 John F. Duane and Mary E. Northridge
 The Gendal Family Foundation
 Dr. Michael F. Giordano
 Global Health Strategies
 Judith Harrington
 Mark Harrington
 Megan Harrington and Jonathan
 Creighton
 Robert C. Henry
 Barbara F. Hughes
 Fannie and Stephen Kahn Charitable
 Foundation
 Winston B. Layne
 Dr. J. Michael McCune III and Dr. Karen
 Kaye Smith-McCune
 Screen Engine / ASI
 Mark M. Sexton and W. Kirk Wallace
 The Estate of Samuel J. Silling
 Audrey Sokoloff and Tim Hosking
 Mrinal Vikram and Kevin Finnegan
 The Andrew David Zacks Foundation

\$1,000 to \$2,499

AbbVie
 Jim Aquino
 Alejandro and Ivy Kwan Arce
 Katherine C. Ash and Thomas M. Ash III
 Jack M. Battaglia
 Beth Israel Deaconess Medical Center I4C
 CAB
 Bob Bronzo
 Karen Bronzo and Jefferson Rabb
 Marisa Cardinale
 Susan Chun
 Marc E. Elovitz
 Jonathan Fine
 Catherine Garzio and Martin Mattes
 Judy and Steven Gluckstern
 Christina and Kenneth Hecht
 Brian Hodge
 IAVI / International AIDS Vaccine Initiative
 Jameel Jiwani
 Tigist Kassahun and Lizzy Lovinger

Noel E.D. Kirnon and Michael D. Paley
 Latino Commission on AIDS
 Michael K. Longacre
 Jeff Meleski and Steve Markov
 Jeff Mendoza and Dr. Chuck Sklar
 National Coalition of STD Directors
 Donesh Olyae
 Otsuka Novel Products GmbH
 Eddie Peltó
 Daniel Ptacek
 Walter Rieman
 Paul Sack
 Dr. Bruce Schackman and Edward K. Sikov
 Andrew C. Schirmeister III
 Evan Schwartz and Robert Fitterman
 H.A. 'Hal' Sedgwick
 Francesco Sedita and Doug Yacka
 The Sigal Family Foundation: David Sigal
 and NY State Senator Brad Hoylman
 Peter Staley
 Henry Thaggert
 Emily Tillman
 Rachel B. Tiven and Seth M. Marnin
 Donn Vecchie-Campbell
 Margaret Rose Vendryes
 Paul Forrest Williams, Jr.
 Wistar Institute BEAT-HIV
 Tim Wuliger
 Max von Zuben

\$500 to \$999

Acadiana Cares
 Moisés Agosto
 Richard Aguiar
 ATAC / AIDS Treatment Activists Coalition
 AVAC / AIDS Vaccine Advocacy Coalition
 Ian and Luann Bailey / Vivid Coffee
 Margot and Robert J. Bazell
 Michael Beltran and Tim Ford
 Frank Bua and Scott Carroll
 Steven J. and Denise Chickery
 Joe Ciancaglini
 Benson Cohen
 Corey Family Trust: Lawrence Corey, MD
 Robert N. Croonquist
 Scott Dainton
 Arianne Z. Dar / New Ground Fund of
 Marin Community Foundation
 Hon. Thomas K. Duane
 EATG / European AIDS Treatment Group

Gene Falk
Steven M. Frank and Dr. Elizabeth S. Powell
Jennifer J. Furin, MD, PhD
Bryn Gay
Aaron Glick
New York State Assembly Member
Deborah J. Glick
Harry Greenwald and Babette Krolik
Roy M. 'Trip' Gulick, MD
J. Drew Hodges and Peter Kukielski
Michael T. Isbell
Richard Jefferys
Rebecca Jordan-Young
Burt R. Lazarin
Kate Lear and Dr. Jonathan LaPook
David C. Levine
Kelsey Louie, Executive Director, GMHC
Saurav Madoori
Vincent Martin and Jason Kirk
Joseph McConnell and Erik Haagensen
Carole D. Mitnick, ScD
Mirla N. and George J. Morrison
Sally Morrison and Tobias Corser
Mylan Inc.
NASTAD / National Alliance of State and Territorial AIDS Directors
National Financial Services
NMAC / National Minority AIDS Council
Ann Northrop
Richard Parsons
Robert H. Remien
Greig Sargeant
Jason Schreiber
Sarah F. and Roy E. Schutzengel
Andrew Shih
Virginia Shubert and David Sipress
Monte Steinman
UCSF DARE Collaboratory CAB
Paolo Danilo Vicino
Wendy Wertheimer

\$250 to \$499

Stuart Anthony
Nick Azrack
John Barone
Danielle Berz
Barbara and Richard Boxer
Rory Bruer
Ama Burnham

Prof. Richard Buxbaum and Catherine Hartshorn
Richard Cardillo
Jill Casid and Anna Campbell
Stephanie and Walter Cowles
Dick Dadey
Lynda M. Dee, Esq.
John Deyling
Peter Morris Dixon
Joy Episalla and Carrie Yamaoka
Andrew Friedman
Ron Goldberg and Joe Chiplock
Rodney and Idan Gould
Craig Greiwe
Dr. Polly F. Harrison
Paula Hartstein and Jonathan Levin
Paul D.C. Huang
Larry Iannotti
Karyn Kaplan and Cindy Kaplan
Paul E. Kennedy
Sung Woon Kil
Susan Leimsider
Jay Leitz
Claire Lennon
Krista Martel / The Well Project
Dr. Brian P. and Laura J. McKenna
Albert S. Messina
Kristin Milot
Fraser D. 'Skip' Mooney
Glenn Nuotio
Kathleen O'Leary
Jason Osher and Richard Schubel
Pam Parker
Diane Parrish
Donna M. Pauldine
Rob and Kate Previti
Mark Quigley
Sara Rafsky
Candis L. and Daniel S. Ramelli
Sheila Reeves
Clifford Richter
Jeffrey H. Schmitt and Michael A. Petrilli
Jane Silver
Paula Silver
John B. Steever, MD
Keith S. Tobin, MD
Cash van Halder
Dorrit Walsh
Thomas P. Wilczak and Steven R. Quinkert
Peter Yorgin

Jenna Young
Vicki Zubovic

plus donations from an additional **298** generous contributors, including Anonymous gifts

We would also like to thank those who gave generously to TAG as part of campaigns hosted by Act Blue Charities, PayPal Charitable Giving, and Network for Good for Facebook fundraising campaigns. TAG received funds by participation in the Amazon Smile program, and also received generous Employee Matching Funds from several business giving platforms. TAG would like to thank artist Keith Mayerson and the Red Hot Organization for generous in-kind donation of goods to support the 2020 Research in Action Awards event that benefitted TAG.

About TAG

Treatment Action Group (TAG) is an independent, activist, and community-based research and policy think tank committed to racial, gender, and LGBTQ+ equity; social justice; and liberation, fighting to end HIV, tuberculosis (TB), and hepatitis C virus (HCV).

TAG catalyzes open collective action by affected communities, scientists, and policymakers to ensure that all people living with or impacted by HIV, TB, or HCV — especially communities of color and other marginalized communities experiencing inequities — receive life-saving prevention, diagnosis, treatment, care, and information.

We are science-based activists working to expand and accelerate vital research and effective community engagement with research and policy institutions for an end to the HIV, TB, and HCV pandemics.

Support TAG

Over the past three decades, TAG has been central to the fight against HIV, HCV, and TB. In 2020, we continued our vital core work to end HIV, HCV, and TB while also applying our expertise to the COVID-19 pandemic. A robust response based on science and driven by community priorities is more crucial than ever.


Make a gift to TAG and help us advocate for the needs of all people affected by HIV, HCV, TB, and COVID-19.

Support TAG today: <https://treatmentactiongroup.salsalabs.org/spring2021>.

Does your organization have a matching gifts program? Don't miss your chance to make a gift that keeps on giving. Complete and send us your company's matching gift form to double your contribution's impact!

TAG Limited Art Editions

Each year, at its Research in Action Awards, TAG presents a new, limited edition work of art. This year, our edition was *Homage to America's Doctor, Anthony S. Fauci* by Keith Mayerson. The package also included other now sold-out elements, and was supported by the generosity of Red Hot and the Marta Heflin Foundation. Many TAG art editions, including a few of artist prints of our 2020 edition, are available for sale to the public. All proceeds benefit TAG's work. If you're interested in purchasing an edition or learning more, detailed information can be found at <https://www.treatmentactiongroup.org/support-us/limited-art-editions/>.



2021 BOARD OF DIRECTORS

PRESIDENT: Robert W. Lennon

SECRETARY: Mrinal Vikram

TREASURER: Laura Morrison

Jim Aquino

Nick Debs

Joy Episalla

Kevin Goetz

Roy Gulick, M.D.

Jameel Jiwani

Richard Lynn, Ph.D., M.P.H.

Robert Monteleone

Eddie Pelto

David Sigal

BOARD PRESIDENT EMERITUS:

Barbara Hughes

TAG Board and staff thank Barbara Hughes for her decades of selfless service and wise leadership. We love you, Barbara.

2021 STAFF

EXECUTIVE DIRECTOR:

Mark Harrington

DEPUTY EXECUTIVE DIRECTOR:

Erica Lessem

TB PROJECT OFFICER:

David Branigan

HCV COMMUNITY

ENGAGEMENT OFFICER:

Joelle Dountio Ofimboudem

ANEA COORDINATOR:

Edric Figueroa

TB PROJECT CO-DIRECTOR:

Mike Frick

DIRECTOR OF POLICY STRATEGY:

Annette Gaudino

HCV PROJECT DIRECTOR:

Bryn Gay

FINANCE MANAGER:

Christopher George

DIRECTOR OF FINANCE AND OPERATIONS:

Sabrina Guerrero-Morris

BASIC SCIENCE, VACCINES, AND CURE PROJECT DIRECTOR:

Richard Jefferys

HIV COMMUNITY ENGAGEMENT OFFICER:

Abraham Johnson

HIV PROJECT DIRECTOR:

Jeremiah Johnson

GRANT OFFICER:

Jason Kirk

SENIOR GOVERNMENT RELATIONS AND POLICY OFFICER:

Elizabeth Lovinger

U.S. AND GLOBAL HEALTH POLICY DIRECTOR:

Suraj Madoori

ADMINISTRATOR:


Joseph McConnell

TB PROJECT CO-DIRECTOR:

Lindsay McKenna

COMMUNICATIONS MANAGER:

Dorrit Walsh



★★★★

CHARITY NAVIGATOR

Four Star Charity

TAG

Treatment Action Group

www.treatmentactiongroup.org

90 Broad Street, Suite 2503
New York, NY 10004
Tel 212.253.7922

tag@treatmentactiongroup.org

TAG is a nonprofit, tax-exempt
501(c)(3) organization.
EIN 13-3624785